Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AstraZeneca plc (AZN) vs Prudential PLC (PUK) Price & Performance

AstraZeneca plcTrade
Prudential PLCTrade

Price performance (Past 24H)

Key statistics

AstraZeneca plc vs Prudential PLC — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while Prudential PLC trades at $27.63 (market cap $34.02B). The key difference: AstraZeneca plc is far larger — about 7.3× Prudential PLC's market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.

AZNPUK
Market Cap
$248.14B$34.02B
Sector
HealthFinancials
52-Week High
$209.48$33.61
52-Week Low
$147.06$24.98
Enterprise Value
$275.41B$35.46B
Dividend Yield
2.01%1.94%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AstraZeneca plc

AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.

The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.

Prudential PLC

Prudential PLC (PUK) trades at $28.22, down 0.21% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The stock shows strong fundamentals with a P/E of 8.92, net income margin of 14.52%, and ROE of 21.15%. Recent earnings beat expectations in Q4 2025, and cash flow from operations reached $3.61B in 2024. However, news of China taxing offshore insurance policies caused a recent sell-off, highlighting regulatory risks.

The outlook for PUK is mixed; solid profitability and low valuation metrics provide upside potential, supported by a 50% analyst buy rating. Key risks include exposure to Chinese regulatory changes and competitive pressures in Asia. Earnings growth and strategic focus on capital-light operations are catalysts, but investor sentiment remains cautious due to near-term headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN

About Prudential PLC

Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.

Read more on PUK